National Cancer Institute–Pediatric MATCH (Molecular Analysis for Therapeutic Choice) trial schema. CR, complete response; FGFR, fibroblast growth factor receptor; mTOR, mechanistic target of rapamycin; PARP, polyadenosine diphosphate-ribose polymerase; PD, progressive disease; PI3K, phosphatidylinositol 3-kinase; PR, partial response; SD, stable disease. Reprinted with permission.17